Neupro (rotigotin) is a new dopamine agonist formulated as slow release transdermal patches. The indication is "initial treatment of idiopathic Parkinson's disease as monotherapy (IPS)".
The symptomatic efficiency of Neupro is better than placebo, but not as good as the oral dopamine agonist ropinirol (Requip).
There are frequent local skin reactions. Additional common adverse effects are similar to the other dopamine agonists and include:
Those appear in the same frequency as for ropinirol.
The daily cost of Neupro is approximately 70 dkr. That is largely in same price category as the other non-ergot derivated dopamine agonists (Requip and Sifrol/mirapexin (pramipexol) on the market.
IRF does not recommend the routine use of Neupro, since the product apparently is less effective, and does not benefit in terms of neither adverse effects nor costs, compared to other available dopamine agonists. Certain patient could possibly benefit from the transdermal formulation.
Neupro was marketed 9 October 2006 and is covered under the rules of general reimbursement.
Institute for Rational Pharmacotherapy, 18 October 2006